Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Oct 26:4:182.
doi: 10.3389/fmed.2017.00182. eCollection 2017.

Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework

Marta Carvalho  1 , Bruno Sepodes  1 , Ana Paula Martins  1
Affiliations
Review

Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework

Marta Carvalho et al. Front Med (Lausanne). .

Abstract

Advanced therapy medicinal products (ATMPs) have a massive potential to address existing unmet medical needs. Specifically, gene therapy medicinal products (GTMPs) may potentially provide cure for several genetic diseases. In Europe, the ATMP regulation was fully implemented in 2009 and, at this point, the Committee for Advanced Therapies was created as a dedicated group of specialists to evaluate medicinal products requiring specific expertise in this area. To date, there are three authorized GTMPs, and the first one was approved in 2012. Broad research has been conducted in this field over the last few decades and different clinical applications are being investigated worldwide, using different strategies that range from direct gene replacement or addition to more complex pathways such as specific gene editing or RNA targeting. Important safety risks, limited efficacy, manufacturing hurdles, or ethical conflicts may represent challenges in the success of a candidate GTMP. During the development process, it is fundamental to take such aspects into account and establish overcoming strategies. This article reviews the current European legal framework of ATMPs, provides an overview of the clinical applications for approved and investigational GTMPs, and discusses critical challenges in the development of GTMPs.

Keywords: Committee for Advanced Therapies; advanced therapy medicinal products; drug development; gene delivery vector; gene therapy.

PubMed Disclaimer

References

    1. Hanna E, Rémuzat C, Auquier P, Toumi M. Advanced therapy medicinal products: current and future perspectives. J Mark Access Heal Policy (2016) 4:1–10. 10.3402/jmahp.v4.31036 - DOI - PMC - PubMed
    1. Wang D, Gao G. State-of-the-art human gene therapy: part I. Gene delivery technologies. Discov Med (2015) 18:67–77. - PMC - PubMed
    1. Wirth T, Parker N, Ylä-Herttuala S. History of gene therapy. Gene (2013) 525:162–9. 10.1016/j.gene.2013.03.137 - DOI - PubMed
    1. EU directives. Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use. Off J Eur Union (2003) L159:46–94.
    1. EU regulation. Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Off J Eur Union (2007) L324:121–37.